Austar Lifesciences (SEHK:6118) - 주가, 뉴스 및 분석

6118 주식 개요

투자 지주 회사인 오스타 라이프사이언스는 중국 본토 및 전 세계의 제약 제조업체와 연구 기관에 통합 엔지니어링 솔루션을 제공하는 기업입니다. 자세한 내용

6118 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

위험 분석

지난 5년간 매년 수익이 0.9% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( HK$338M )

최근 3개월간 주가 변동성

Austar Lifesciences Limited 경쟁사

Viva Biotech Holdings

SEHK:1873

HK$1.9b

China Health Group

SEHK:8225

HK$177.2m

Zhejiang Taimei Medical Technology

SEHK:2576

HK$2.9b

Frontage Holdings

SEHK:1521

HK$2.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Austar Lifesciences
과거 주가
현재 주가	HK$0.66
52주 최고치	HK$2.20
52주 최저치	HK$0.47
베타	1.26
11개월 변경	-15.38%
3개월 변경 사항	-2.94%
1년 변경 사항	-66.67%
33년 변화	-96.24%
5년 변화	-86.19%
IPO 이후 변화	-81.51%

최근 뉴스 및 업데이트

Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Oct 16

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

Aug 28

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Recent updates

Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Oct 16

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

Aug 28

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23

주주 수익률

	6118	HK Life Sciences	HK 마켓
7D	6.5%	-9.0%	0.05%
1Y	-66.7%	-58.7%	11.5%

수익률 대 산업: 6118 지난 1년 동안 -58.7 %를 반환한 Hong Kong Life Sciences 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 6118 지난 1년 동안 11.5 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 6118's price volatile compared to industry and market?
6118 volatility
6118 Average Weekly Movement	17.5%
Life Sciences Industry Average Movement	14.2%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

안정적인 주가: 6118 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 6118 의 주간 변동성( 17% )은 지난 1년 동안 안정적이었지만 여전히 Hong Kong 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1991	1,492	Mars Ho	www.austar.com.hk

투자 지주 회사인 오스타 라이프사이언스는 중국 본토 및 전 세계의 제약 제조업체와 연구 기관에 통합 엔지니어링 솔루션을 제공하는 기업입니다. 이 회사는 액체 및 바이오 프로세스 시스템, 클린룸 및 자동화 제어 및 모니터링 시스템, 분말 및 고체 시스템, GMP 준수 서비스, 생명과학 소모품, 제약 장비 유통 및 대리점 부문을 통해 사업을 운영하고 있습니다. 또한 클린 유틸리티 및 바이오 프로세스 장비, 클린룸, 자동화 제어 및 모니터 시스템, 바이오 프로세스 장비 소모품, 실험실 솔루션도 제공합니다.

Austar Lifesciences Limited 기본 사항 요약

Austar Lifesciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
6118 기본 통계
시가총액	HK$338.30m
수익(TTM)	-HK$20.81m
수익(TTM)	HK$1.66b

0.2x

P/S 비율

-16.3x

P/E 비율

6118 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
6118 손익 계산서(TTM)
수익	CN¥1.55b
수익 비용	CN¥1.25b
총 이익	CN¥294.53m
기타 비용	CN¥313.89m
수익	-CN¥19.35m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.038
총 마진	19.06%
순이익 마진	-1.25%
부채/자본 비율	49.5%

6118 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

6118 주식 개요

위험 분석

Austar Lifesciences Limited 경쟁사

SEHK:1873

HK$1.9b

SEHK:8225

HK$177.2m

SEHK:2576

HK$2.9b

SEHK:1521

HK$2.0b

가격 내역 및 성능

최근 뉴스 및 업데이트

Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

First half 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.078 loss in 1H 2023)

Austar Lifesciences Limited to Report First Half, 2024 Results on Aug 27, 2024

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Recent updates

Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

First half 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.078 loss in 1H 2023)

Austar Lifesciences Limited to Report First Half, 2024 Results on Aug 27, 2024

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.063 loss per share (vs CN¥0.17 profit in FY 2022)

Austar Lifesciences Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

New major risk - Share price stability

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

First half 2023 earnings released: CN¥0.078 loss per share (vs CN¥0.089 profit in 1H 2022)

Investor sentiment deteriorates as stock falls 30%

Austar Lifesciences Limited to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.54 in FY 2021)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 25%

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

First half 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.42 in 1H 2021)

Investor sentiment deteriorated over the past week

Austar Lifesciences Limited to Report First Half, 2022 Results on Aug 29, 2022

Austar Lifesciences Limited (SEHK:6118) acquired an unknown minority interest in Noozle Fluid Technology (Shanghai) Co., Ltd..

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Less than half of directors are independent

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Investor sentiment improved over the past week

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorated over the past week

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

First half 2021 earnings released: EPS CN¥0.42 (vs CN¥0.025 in 1H 2020)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Full year 2020 earnings released: EPS CN¥0.065 (vs CN¥0.016 in FY 2019)

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.016 in FY 2019)

Austar Lifesciences Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

An affiliate of Pall Corporation entered into an agreement to acquire 60% in PALL-AUSTAR Lifesciences Limited from Austar Lifesciences Limited (SEHK:6118) for approximately CNY 220 million.

New 90-day high: HK$6.15

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

New 90-day high: HK$4.02